Esperion Therapeutics | ESPR - Cost Of Sales


Esperion Therapeutics reported $27.85M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Cipla INR 26.32B 2.79B Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Cytokinetics USD 160K 104.24M Mar/2026
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Geron USD 1.69M 386K Mar/2026
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 955M 503M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024